BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

(BHVN)
  Report
Real-time Estimate Cboe BZX  -  05/24 02:40:19 pm EDT
143.31 USD   +0.21%
08:18aBiohaven Pharmaceutical - US FDA ACCEPTS FOR REVIEW BIOHAVEN'S NEW DRUG APPLICATION (NDA) FILING OF INTRANASAL ZAVEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE
AQ
05/23Biohaven's Late-stage Spinocerebellar Ataxia Trial's Primary Endpoint Fails to Reach Statistical Significance
MT
05/23Biohaven Says US FDA Accepts for Review NDA Filing of Intranasal Zavegepant for Acute Treatment of Migraine
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
141.73(c) 141.05(c) 142.03(c) 143(c) 143.07 Last
1 893 756 1 919 225 2 414 739 2 111 117 1 160 745 Volume
-0.04% -0.48% +0.69% +0.68% +0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 054 M - -
Net income 2022 -672 M - -
Net Debt 2022 52,9 M - -
P/E ratio 2022 -13,1x
Yield 2022 -
Sales 2023 1 191 M - -
Net income 2023 -362 M - -
Net Debt 2023 614 M - -
P/E ratio 2023 -28,3x
Yield 2023 -
Capitalization 10 159 M 10 159 M -
EV / Sales 2022 9,69x
EV / Sales 2023 9,05x
Nbr of Employees 928
Free-Float 86,1%
More Financials
Company
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates... 
More about the company
Ratings of Biohaven Pharmaceutical Holding Company Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
08:18aBiohaven Pharmaceutical - US FDA ACCEPTS FOR REVIEW BIOHAVEN'S NEW DRUG APPLICATION (ND..
AQ
05/23Biohaven's Late-stage Spinocerebellar Ataxia Trial's Primary Endpoint Fails to Reach St..
MT
05/23Biohaven Says US FDA Accepts for Review NDA Filing of Intranasal Zavegepant for Acute T..
MT
05/23US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Za..
PR
05/23US FDA Accepts for Review Biohaven's New Drug Application filing of Intranasal Zavegepa..
CI
05/23Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocere..
PR
05/23Biohaven Pharmaceutical Holding Company Ltd. Provides Update on Phase 3 Clinical Trial ..
CI
05/17BIOHAVEN INVESTOR ALERT BY THE FORME : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
05/13Shareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Ph..
PR
05/13PUMP / DUMP #31 : The week's gainers and losers
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/11Cantor Fitzgerald Downgrades Biohaven Pharmaceutical to Neutral From Overweight, Lowers..
MT
05/11HC Wainwright Downgrades Biohaven Pharmaceutical Holding Company to Neutral From Buy, L..
MT
05/11Morgan Stanley Raises Biohaven Pharmaceutical Holding's Price Target to $148.50 From $1..
MT
05/11Biohaven reports first quarter 2022 financial results and reports recent business devel..
AQ
More news
News in other languages on BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
05/23Le critère d'évaluation principal de l'essai de stade avancé sur l'ataxie spinocérébell..
05/23Biohaven déclare que la FDA américaine accepte d'examiner le dépôt de la demande de NDA..
05/23La FDA américaine accepte d'examiner le dépôt par Biohaven d'une demande d'autorisation..
05/23Biohaven Pharmaceutical Holding Company Ltd. Fournit une mise à jour sur l'essai cliniq..
05/13PUMP / DUMP #59 : Les Tops & Flops de la semaine
More news
Analyst Recommendations on BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
More recommendations
Chart BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Duration : Period :
Biohaven Pharmaceutical Holding Company Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 143,00 $
Average target price 158,35 $
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Vladimir Coric Chairman & Chief Executive Officer
Matthew Buten Chief Financial Officer
Charles Conway Chief Scientific Officer
Elyse Stock Chief Medical Officer
Melissa Beiner Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.3.77%10 159
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688